Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Ioanna Gazouli(University Hospital of Ioannina), Amanda Psyrri(National and Kapodistrian University of Athens), Anastasios Pantazopoulos(University General Hospital Attikon), Georgios Kavourakis(University General Hospital Attikon), Μaria Anastasiou(National and Kapodistrian University of Athens), Anastasios Kyriazoglou(Alexandra Hospital), Panayiotis J. Papagelopoulos(National and Kapodistrian University of Athens), Vasileios Kontogeorgakos(University General Hospital Attikon), Ioannis Chatzidakis(University General Hospital Attikon), Maria Prevezanou(University General Hospital Attikon), Ioannis Kotsantis(National and Kapodistrian University of Athens), Panagiota Economopoulou(National and Kapodistrian University of Athens)
Cited by 58
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Activation of Wnt Signaling Pathway by Human Papillomavirus E6 and E7 Oncogenes in HPV16-Positive Oropharyngeal Squamous Carcinoma Cells
|Molecular Cancer Research|2010|120